The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- India Plans to Exempt Domestic Study for Japan-Approved Drugs
September 4, 2018
- MHLW, METI Seek 3-Year Extension for Temporary R&D Tax Credit Measures
September 3, 2018
- FY2019 Revision Should Cover Only “Half a Year’s Worth” of Price Tweaks, MHLW Insurance Chief Says for Clarification
September 3, 2018
- April 2019 Price Cut Wouldn’t Fit the Purpose of Tax Tweak: MHLW Insurance Chief
August 31, 2018
- MHLW to Steadily Promote Pharma Industry through Comprehensive Strategy: New Health Policy Chief
August 31, 2018
- Kyorin’s OAB Drug Vibegron and More Clear MHLW Panel; Official Nod Anticipated September
August 31, 2018
- Panel Gives Blessing for Pfizer’s Lorlatinib, Astellas AML Drug; Approval Expected in September
August 30, 2018
- MHLW to Request Record Budget of Nearly 31.9 Trillion Yen for FY2019
August 30, 2018
- MHLW Panel Backs Orphan Status for SMA Gene Therapy, CAR-Ts
August 30, 2018
- MHLW Discussing Use of Data from “Specified Clinical Research” in Application Dossiers, Will Issue Preliminary Conclusions by March
August 29, 2018
- Chuikyo Might Take Up "Biosames" for Discussion Around Autumn: Ex-Pharmaceutical Management Director
August 28, 2018
- Japan Eyes State Funds to Boost Sakigake Review Staffers: FY2019 Budget Request
August 27, 2018
- MHLW to Expand MID-NET and Coordinate with Other Databases and Registries to Improve Safety Measures: Official
August 27, 2018
- It’s Too Early to Introduce Incentives for Biosimilar Use: MHLW Official
August 27, 2018
- MHLW to Issue Optimal Use Guidelines for Imfinzi, Might Make Changes on Latest Data
August 23, 2018
- MHLW Orders Label Revisions for 7 Flu Drugs Including Tamiflu
August 23, 2018
- Chuikyo Discusses ICER Evaluations for Drugs with Multiple Indications
August 23, 2018
- Chuikyo to Allow “Ranged” ICER Values in Cost-Effective Assessment
August 23, 2018
- Chuikyo Members Call for More Info Disclosure for CEA Scheme
August 23, 2018
- Chuikyo OKs Pricing of Entyvio, Imfinzi, Gazyva and More; Listing on Aug. 29
August 22, 2018
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…